Phase I Study of Fluvastatin/Celecoxib Combination in Children with Relapsing or Refractory Low or High Grade Glioma - First Results
The first results of a phase I study with fluvastatin/celecoxib in children with glioma were presented during the conference of the International Society of Paediatric Oncology (SIOP) in Lyon in October 2019.
As preclinical and clinical data support the anticancer activity of fluvastatin and celecoxib in low grade gliomas (LGG), a phase I trial was designed to evaluate the combination in children with relapsing or refractory glioma. Twenty patients were included. The combination of the two drugs displayed very limited toxicity with interesting preliminary activity in patients with LGG.
A phase 2 study in patients with LGG should be encouraged, and support of the Anticancer Fund is currently being discussed with the French paediatric oncologists.
Read more on the trial here.